{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T11:59:30Z","timestamp":1794916770219,"version":"4.9.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T00:00:00Z","timestamp":1731888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004080","name":"Korea Drug Development Fund","doi-asserted-by":"publisher","award":["HN21C0764"],"award-info":[{"award-number":["HN21C0764"]}],"id":[{"id":"10.13039\/501100004080","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00260454"],"award-info":[{"award-number":["RS-2023-00260454"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2016M3A9D3900438"],"award-info":[{"award-number":["2016M3A9D3900438"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-024-53996-7","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T05:02:14Z","timestamp":1731906134000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters"],"prefix":"10.1038","volume":"15","author":[{"given":"Hyung Bae","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0472-8010","authenticated-orcid":false,"given":"Sang Il","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Mi","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miseung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7546-2491","authenticated-orcid":false,"given":"Siwon","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeonmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TaeJin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungbin","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga Ram","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1006-2689","authenticated-orcid":false,"given":"Hyewon","family":"Youn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2441-3374","authenticated-orcid":false,"given":"Eun Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woo Chan","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3501-212X","authenticated-orcid":false,"given":"Sang J.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4873-8031","authenticated-orcid":false,"given":"Junho","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1635-173X","authenticated-orcid":false,"given":"Kyungho","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,18]]},"reference":[{"key":"53996_CR1","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/nri1729","volume":"5","author":"MH Kershaw","year":"2005","unstructured":"Kershaw, M. H., Teng, M. W., Smyth, M. J. & Darcy, P. K. Supernatural T cells: genetic modification of T cells for cancer therapy. Nat. Rev. Immunol. 5, 928\u2013940 (2005).","journal-title":"Nat. Rev. Immunol."},{"key":"53996_CR2","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507\u20131517 (2014).","journal-title":"N. Engl. J. Med."},{"key":"53996_CR3","first-page":"1","volume":"41","author":"S Gill","year":"2021","unstructured":"Gill, S. & Brudno, J. N. CAR T-Cell therapy in hematologic malignancies: Clinical role, toxicity, and unanswered questions. Am. Soc. Clin. Oncol. Educ. Book 41, 1\u201320 (2021).","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"53996_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq, S., Hackett, C. S. & Brentjens, R. J. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat. Rev. Clin. Oncol. 17, 147\u2013167 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"53996_CR5","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/mt.2013.17","volume":"21","author":"CH Lamers","year":"2013","unstructured":"Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol. Ther. 21, 904\u2013912 (2013).","journal-title":"Mol. Ther."},{"key":"53996_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","volume":"18","author":"RA Morgan","year":"2010","unstructured":"Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M. & Rosenberg, S. A. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843\u2013851 (2010).","journal-title":"Mol. Ther."},{"key":"53996_CR7","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","volume":"66","author":"FC Thistlethwaite","year":"2017","unstructured":"Thistlethwaite, F. C. et al. The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunol. Immunother. 66, 1425\u20131436 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"53996_CR8","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.cell.2016.01.011","volume":"164","author":"KT Roybal","year":"2016","unstructured":"Roybal, K. T. et al. Precision tumor recognition by T cells with combinatorial antigen-Sensing Circuits. Cell 164, 770\u2013779 (2016).","journal-title":"Cell"},{"key":"53996_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","volume":"35","author":"S Srivastava","year":"2019","unstructured":"Srivastava, S. et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell 35, 489\u2013503 e488 (2019).","journal-title":"Cancer Cell"},{"key":"53996_CR10","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt.2459","volume":"31","author":"CC Kloss","year":"2013","unstructured":"Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M. & Sadelain, M. Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nat. Biotechnol. 31, 71\u201375 (2013).","journal-title":"Nat. Biotechnol."},{"key":"53996_CR11","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1158\/2326-6066.CIR-13-0008","volume":"1","author":"E Lanitis","year":"2013","unstructured":"Lanitis, E. et al. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunol. Res. 1, 43\u201353 (2013).","journal-title":"Cancer Immunol. Res."},{"key":"53996_CR12","doi-asserted-by":"publisher","first-page":"215ra172","DOI":"10.1126\/scitranslmed.3006597","volume":"5","author":"VD Fedorov","year":"2013","unstructured":"Fedorov, V. D., Themeli, M. & Sadelain, M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci. Transl. Med. 5, 215ra172 (2013).","journal-title":"Sci. Transl. Med."},{"key":"53996_CR13","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/leu.2010.75","volume":"24","author":"V Hoyos","year":"2010","unstructured":"Hoyos, V. et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety. Leukemia 24, 1160\u20131170 (2010).","journal-title":"Leukemia"},{"key":"53996_CR14","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1182\/blood-2016-08-736041","volume":"129","author":"SK Tasian","year":"2017","unstructured":"Tasian, S. K. et al. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia. Blood 129, 2395\u20132407 (2017).","journal-title":"Blood"},{"key":"53996_CR15","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1172\/JCI84813","volume":"126","author":"PJ Paszkiewicz","year":"2016","unstructured":"Paszkiewicz, P. J. et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J. Clin. Invest. 126, 4262\u20134272 (2016).","journal-title":"J. Clin. Invest."},{"key":"53996_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong, M., Clubb, J. D. & Chen, Y. Y. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell 38, 473\u2013488 (2020).","journal-title":"Cancer Cell"},{"key":"53996_CR17","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1158\/0008-5472.CAN-11-3890","volume":"72","author":"K Urbanska","year":"2012","unstructured":"Urbanska, K. et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 72, 1844\u20131852 (2012).","journal-title":"Cancer Res."},{"key":"53996_CR18","doi-asserted-by":"publisher","first-page":"6436","DOI":"10.1158\/1078-0432.CCR-12-1449","volume":"18","author":"K Tamada","year":"2012","unstructured":"Tamada, K. et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin. Cancer Res. 18, 6436\u20136445 (2012).","journal-title":"Clin. Cancer Res."},{"key":"53996_CR19","doi-asserted-by":"publisher","first-page":"E450","DOI":"10.1073\/pnas.1524193113","volume":"113","author":"JS Ma","year":"2016","unstructured":"Ma, J. S. et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc. Natl. Acad. Sci. USA 113, E450\u2013E458 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"53996_CR20","doi-asserted-by":"publisher","first-page":"E459","DOI":"10.1073\/pnas.1524155113","volume":"113","author":"DT Rodgers","year":"2016","unstructured":"Rodgers, D. T. et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc. Natl. Acad. Sci. USA 113, E459\u2013E468 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"53996_CR21","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/j.cell.2018.03.038","volume":"173","author":"JH Cho","year":"2018","unstructured":"Cho, J. H., Collins, J. J. & Wong, W. W. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 173, 1426\u20131438.e1411 (2018).","journal-title":"Cell"},{"key":"53996_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10565-7","volume":"10","author":"YG Lee","year":"2019","unstructured":"Lee, Y. G. et al. Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters. Nat. Commun. 10, 2681 (2019).","journal-title":"Nat. Commun."},{"key":"53996_CR23","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/S0167-5699(99)01507-8","volume":"20","author":"RT Costello","year":"1999","unstructured":"Costello, R. T., Gastaut, J. A. & Olive, D. What is the real role of CD40 in cancer immunotherapy? Immunol. Today 20, 488\u2013493 (1999).","journal-title":"Immunol. Today"},{"key":"53996_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1146\/annurev.immunol.16.1.111","volume":"16","author":"IS Grewal","year":"1998","unstructured":"Grewal, I. S. & Flavell, R. A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16, 111\u2013135 (1998).","journal-title":"Annu. Rev. Immunol."},{"key":"53996_CR25","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3109\/08923973.2014.890626","volume":"36","author":"SB Hassan","year":"2014","unstructured":"Hassan, S. B., Sorensen, J. F., Olsen, B. N. & Pedersen, A. E. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol. Immunotoxicol. 36, 96\u2013104 (2014).","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"53996_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide, R. H. CD40 Agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 71, 47\u201358 (2020).","journal-title":"Annu. Rev. Med."},{"key":"53996_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1084\/jem.182.1.33","volume":"182","author":"D Hollenbaugh","year":"1995","unstructured":"Hollenbaugh, D. et al. Expression of functional CD40 by vascular endothelial cells. J. Exp. Med. 182, 33\u201340 (1995).","journal-title":"J. Exp. Med."},{"key":"53996_CR28","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0167-5699(98)01340-1","volume":"19","author":"LS Young","year":"1998","unstructured":"Young, L. S., Eliopoulos, A. G., Gallagher, N. J. & Dawson, C. W. CD40 and epithelial cells: across the great divide. Immunol. Today 19, 502\u2013506 (1998).","journal-title":"Immunol. Today"},{"key":"53996_CR29","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.4049\/jimmunol.160.3.1053","volume":"160","author":"Y Zhang","year":"1998","unstructured":"Zhang, Y., Cao, H. J., Graf, B., Meekins, H., Smith, T. J. & Phipps, R. P. CD40 engagement up-regulates cyclooxygenase-2 expression and prostaglandin E2 production in human lung fibroblasts. J. Immunol. 160, 1053\u20131057 (1998).","journal-title":"J. Immunol."},{"key":"53996_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","volume":"15","author":"SS Neelapu","year":"2018","unstructured":"Neelapu, S. S. et al. Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat. Rev. Clin. Oncol. 15, 47\u201362 (2018).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"53996_CR31","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739\u2013748 (2018).","journal-title":"Nat. Med."},{"key":"53996_CR32","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A. & Sadelain, M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat. Med. 24, 731\u2013738 (2018).","journal-title":"Nat. Med."},{"key":"53996_CR33","doi-asserted-by":"publisher","first-page":"130","DOI":"10.5483\/BMBRep.2014.47.3.006","volume":"47","author":"H Kim","year":"2014","unstructured":"Kim, H., Yoon, S. & Chung, J. In vitro and in vivo application of anti-cotinine antibody and cotinine-conjugated compounds. BMB Rep. 47, 130\u2013134 (2014).","journal-title":"BMB Rep."},{"key":"53996_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jconrel.2016.03.006","volume":"229","author":"K Heo","year":"2016","unstructured":"Heo, K. et al. An aptamer-antibody complex (oligobody) as a novel delivery platform for targeted cancer therapies. J. Control Release 229, 1\u20139 (2016).","journal-title":"J. Control Release"},{"key":"53996_CR35","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1002\/anie.201811509","volume":"58","author":"B Yu","year":"2019","unstructured":"Yu, B. et al. A hybrid platform based on a bispecific peptide-antibody complex for targeted cancer therapy. Angew. Chem. Int. Ed. Engl. 58, 2005\u20132010 (2019).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"53996_CR36","doi-asserted-by":"publisher","first-page":"1089369","DOI":"10.3389\/fimmu.2022.1089369","volume":"13","author":"HY Kang","year":"2022","unstructured":"Kang, H. Y. et al. A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets. Front. Immunol. 13, 1089369 (2022).","journal-title":"Front. Immunol."},{"key":"53996_CR37","doi-asserted-by":"publisher","first-page":"e0146907","DOI":"10.1371\/journal.pone.0146907","volume":"11","author":"A Yoon","year":"2016","unstructured":"Yoon, A., Shin, J. W., Kim, S., Kim, H. & Chung, J. Chicken scFvs with an artificial cysteine for site-directed conjugation. PLoS One 11, e0146907 (2016).","journal-title":"PLoS One"},{"key":"53996_CR38","doi-asserted-by":"publisher","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","volume":"115","author":"S Viaud","year":"2018","unstructured":"Viaud, S. et al. Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory. Proc. Natl. Acad. Sci. USA 115, E10898\u2013E10906 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"53996_CR39","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten, F. R. & Grivennikov, S. I. Inflammation and cancer: Triggers, mechanisms, and consequences. Immunity 51, 27\u201341 (2019).","journal-title":"Immunity"},{"key":"53996_CR40","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1084\/jem.194.7.953","volume":"194","author":"W Weninger","year":"2001","unstructured":"Weninger, W., Crowley, M. A., Manjunath, N. & von Andrian, U. H. Migratory properties of naive, effector, and memory CD8(+) T cells. J. Exp. Med. 194, 953\u2013966 (2001).","journal-title":"J. Exp. Med."},{"key":"53996_CR41","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1182\/blood-2006-06-028001","volume":"109","author":"PR Hess","year":"2007","unstructured":"Hess, P. R. et al. Selective deletion of antigen-specific CD8+ T cells by MHC class I tetramers coupled to the type I ribosome-inactivating protein saporin. Blood 109, 3300\u20133307 (2007).","journal-title":"Blood"},{"key":"53996_CR42","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.4049\/jimmunol.0903931","volume":"184","author":"BG Vincent","year":"2010","unstructured":"Vincent, B. G. et al. Toxin-coupled MHC class I tetramers can specifically ablate autoreactive CD8+ T cells and delay diabetes in nonobese diabetic mice. J. Immunol. 184, 4196\u20134204 (2010).","journal-title":"J. Immunol."},{"key":"53996_CR43","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/nbt.3584","volume":"34","author":"R Palchaudhuri","year":"2016","unstructured":"Palchaudhuri, R. et al. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat. Biotechnol. 34, 738\u2013745 (2016).","journal-title":"Nat. Biotechnol."},{"key":"53996_CR44","doi-asserted-by":"crossref","unstructured":"Persaud, S. P. et al. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 131, e145501 (2021).","DOI":"10.1172\/JCI145501"},{"key":"53996_CR45","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","volume":"34","author":"JN Brudno","year":"2016","unstructured":"Brudno, J. N. et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34, 1112\u20131121 (2016).","journal-title":"J. Clin. Oncol."},{"key":"53996_CR46","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/bjh.14923","volume":"179","author":"Y Chen","year":"2017","unstructured":"Chen, Y. et al. Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation. Br. J. Haematol. 179, 598\u2013605 (2017).","journal-title":"Br. J. Haematol."},{"key":"53996_CR47","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1182\/blood-2015-08-664250","volume":"127","author":"E Jacoby","year":"2016","unstructured":"Jacoby, E., Yang, Y., Qin, H., Chien, C. D., Kochenderfer, J. N. & Fry, T. J. Murine allogeneic CD19 CAR T cells harbor potent antileukemic activity but have the potential to mediate lethal GVHD. Blood 127, 1361\u20131370 (2016).","journal-title":"Blood"},{"key":"53996_CR48","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nm.4258","volume":"23","author":"A Ghosh","year":"2017","unstructured":"Ghosh, A. et al. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity. Nat. Med. 23, 242\u2013249 (2017).","journal-title":"Nat. Med."},{"key":"53996_CR49","doi-asserted-by":"publisher","first-page":"3596","DOI":"10.1158\/0008-5472.CAN-15-0159","volume":"75","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Res. 75, 3596\u20133607 (2015).","journal-title":"Cancer Res."},{"key":"53996_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-14749-3","volume":"7","author":"S Park","year":"2017","unstructured":"Park, S. et al. Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity. Sci. Rep. 7, 14366 (2017).","journal-title":"Sci. Rep."},{"key":"53996_CR51","doi-asserted-by":"crossref","unstructured":"Castellarin, M. et al. A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. JCI Insight 5, e136012 (2020).","DOI":"10.1172\/jci.insight.136012"},{"key":"53996_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s12896-019-0537-3","volume":"19","author":"A Juillerat","year":"2019","unstructured":"Juillerat, A. et al. Modulation of chimeric antigen receptor surface expression by a small molecule switch. BMC Biotechnol. 19, 44 (2019).","journal-title":"BMC Biotechnol."},{"key":"53996_CR53","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1016\/j.ymthe.2020.06.004","volume":"28","author":"SA Richman","year":"2020","unstructured":"Richman, S. A., Wang, L. C., Moon, E. K., Khire, U. R., Albelda, S. M. & Milone, M. C. Ligand-induced degradation of a CAR permits reversible remote control of CAR T cell activity in vitro and in vivo. Mol. Ther. 28, 1600\u20131613 (2020).","journal-title":"Mol. Ther."},{"key":"53996_CR54","doi-asserted-by":"crossref","unstructured":"Jan, M. et al. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci. Transl. Med. 13, eabb6295 (2021).","DOI":"10.1126\/scitranslmed.abb6295"},{"key":"53996_CR55","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1016\/j.cell.2022.03.041","volume":"185","author":"L Labanieh","year":"2022","unstructured":"Labanieh, L. et al. Enhanced safety and efficacy of protease-regulated CAR-T cell receptors. Cell 185, 1745\u20131763.e1722 (2022).","journal-title":"Cell"},{"key":"53996_CR56","doi-asserted-by":"publisher","first-page":"e1342909","DOI":"10.1080\/2162402X.2017.1342909","volume":"6","author":"E Pishali Bejestani","year":"2017","unstructured":"Pishali Bejestani, E. et al. Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. Oncoimmunology 6, e1342909 (2017).","journal-title":"Oncoimmunology"},{"key":"53996_CR57","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1080\/19420862.2016.1185581","volume":"8","author":"R Adams","year":"2016","unstructured":"Adams, R. et al. Extending the half-life of a fab fragment through generation of a humanized anti-human serum albumin Fv domain: An investigation into the correlation between affinity and serum half-life. MAbs 8, 1336\u20131346 (2016).","journal-title":"MAbs"},{"key":"53996_CR58","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1182\/blood.2020009759","volume":"137","author":"M Wermke","year":"2021","unstructured":"Wermke, M. et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed\/refractory AML. Blood 137, 3145\u20133148 (2021).","journal-title":"Blood"},{"key":"53996_CR59","first-page":"176","volume":"20","author":"DK Li","year":"2020","unstructured":"Li, D. K. & Wang, W. Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies. Oncol. Lett. 20, 176 (2020).","journal-title":"Oncol. Lett."},{"key":"53996_CR60","doi-asserted-by":"crossref","unstructured":"Bonnans, C. et al. CD40 agonist-induced IL-12p40 potentiates hepatotoxicity. J. Immunother. Cancer 8, e000624 (2020).","DOI":"10.1136\/jitc-2020-000624"},{"key":"53996_CR61","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1084\/jem.20060844","volume":"203","author":"C Chiodoni","year":"2006","unstructured":"Chiodoni, C. et al. Triggering CD40 on endothelial cells contributes to tumor growth. J. Exp. Med. 203, 2441\u20132450 (2006).","journal-title":"J. Exp. Med."},{"key":"53996_CR62","doi-asserted-by":"publisher","first-page":"H631","DOI":"10.1152\/ajpheart.00733.2005","volume":"290","author":"T Vowinkel","year":"2006","unstructured":"Vowinkel, T., Wood, K. C., Stokes, K. Y., Russell, J., Krieglstein, C. F. & Granger, D. N. Differential expression and regulation of murine CD40 in regional vascular beds. Am. J. Physiol. Heart Circ. Physiol. 290, H631\u2013H639 (2006).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"53996_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40173-5","volume":"14","author":"M Guo","year":"2023","unstructured":"Guo, M. et al. Guided construction of single cell reference for human and mouse lung. Nat. Commun. 14, 4566 (2023).","journal-title":"Nat. Commun."},{"key":"53996_CR64","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1007\/s00134-004-2370-x","volume":"30","author":"SE Orfanos","year":"2004","unstructured":"Orfanos, S. E., Mavrommati, I., Korovesi, I. & Roussos, C. Pulmonary endothelium in acute lung injury: from basic science to the critically ill. Intensive Care Med. 30, 1702\u20131714 (2004).","journal-title":"Intensive Care Med."},{"key":"53996_CR65","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","volume":"35","author":"NF Kuhn","year":"2019","unstructured":"Kuhn, N. F. et al. CD40 Ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 35, 473\u2013488.e476 (2019).","journal-title":"Cancer Cell"},{"key":"53996_CR66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0378-4274(99)00070-3","volume":"109","author":"O Riah","year":"1999","unstructured":"Riah, O., Dousset, J. C., Courriere, P., Stigliani, J. L., Baziard-Mouysset, G. & Belahsen, Y. Evidence that nicotine acetylcholine receptors are not the main targets of cotinine toxicity. Toxicol. Lett. 109, 21\u201329 (1999).","journal-title":"Toxicol. Lett."},{"key":"53996_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2021.758252","volume":"15","author":"X Tan","year":"2021","unstructured":"Tan, X., Vrana, K. & Ding, Z. M. Cotinine: Pharmacologically active metabolite of nicotine and neural mechanisms for its actions. Front. Behav. Neurosci. 15, 758252 (2021).","journal-title":"Front. Behav. Neurosci."},{"key":"53996_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","volume":"18","author":"P Khongorzul","year":"2020","unstructured":"Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U. & Zhang, J. Antibody-drug conjugates: A comprehensive review. Mol. Cancer Res. 18, 3\u201319 (2020).","journal-title":"Mol. Cancer Res"},{"key":"53996_CR69","doi-asserted-by":"crossref","unstructured":"Andris-Widhopf, J., Steinberger, P., Fuller R., Rader, C. & Barbas, C. F. 3rd Generation of human scFv antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences. Cold Spring Harb. Protoc. 2011, pdb.prot065573 (2011).","DOI":"10.1101\/pdb.prot065573"},{"key":"53996_CR70","doi-asserted-by":"publisher","first-page":"3875","DOI":"10.1182\/blood-2010-01-265041","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J. N., Yu, Z., Frasheri, D., Restifo, N. P. & Rosenberg, S. A. Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood 116, 3875\u20133886 (2010).","journal-title":"Blood"},{"key":"53996_CR71","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.cca.2010.04.027","volume":"411","author":"S Park","year":"2010","unstructured":"Park, S., Lee, D. H., Park, J. G., Lee, Y. T. & Chung, J. A sensitive enzyme immunoassay for measuring cotinine in passive smokers. Clin. Chim. Acta 411, 1238\u20131242 (2010).","journal-title":"Clin. Chim. Acta"},{"key":"53996_CR72","doi-asserted-by":"publisher","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","volume":"116","author":"JN Kochenderfer","year":"2010","unstructured":"Kochenderfer, J. N. et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 116, 4099\u20134102 (2010).","journal-title":"Blood"},{"key":"53996_CR73","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood-2006-03-007427","volume":"108","author":"R Chakraverty","year":"2006","unstructured":"Chakraverty, R. et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood 108, 2106\u20132113 (2006).","journal-title":"Blood"},{"key":"53996_CR74","doi-asserted-by":"publisher","first-page":"5572","DOI":"10.4049\/jimmunol.1200045","volume":"189","author":"HW Li","year":"2012","unstructured":"Li, H. W., Sachs, J., Pichardo, C., Bronson, R., Zhao, G. & Sykes, M. Nonalloreactive T cells prevent donor lymphocyte infusion-induced graft-versus-host disease by controlling microbial stimuli. J. Immunol. 189, 5572\u20135581 (2012).","journal-title":"J. Immunol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53996-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53996-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53996-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T06:05:18Z","timestamp":1731909918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-53996-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,18]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["53996"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-53996-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,18]]},"assertion":[{"value":"30 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.C. and E.Y.C. are founders and shareholders of Ticaros Inc. H.B.P., J.E.L., and G.R.J. are currently employees of Ticaros. K.C., J.C., H.B.P., K.H.K., S.I.K., and G.R.J. are co-inventors on the pending patent for anti-CD40 switchable CAR T cells. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9917"}}